Darzalex godkänt som förstalinjens behandling vid multipelt myelom

Godkännandet gäller för daratumumab i kombination med bortezomoid, melfalan och prednison för behandling av vuxna med nydiagnosticerat multipelt myelom.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has granted marketing authorisation for Darzalex® (daratumumab) for use as frontline (initial) therapy. The approval is for the use of daratumumab in combination with bortezomib, melphalan and prednisone (VMP), for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

Läs det internationella pressmeddelandet